Codexis, Inc.  

(Public, NASDAQ:CDXS)   Watch this stock  
Find more results for CDXS
4.05
+0.01 (0.25%)
May 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.02 - 4.10
52 week 2.93 - 4.72
Open 4.07
Vol / Avg. 50,419.00/71,382.00
Mkt cap 167.68M
P/E     -
Div/yield     -
EPS -0.23
Shares 40.79M
Beta -0.01
Inst. own 58%
Aug 9, 2016
Q2 2016 Codexis Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
May 25, 2016
Codexis Inc at B. Riley Investor Conference - Webcast
May 9, 2016
Q1 2016 Codexis Inc Earnings Call - Webcast
May 9, 2016
Q1 2016 Codexis Inc Earnings Release
Mar 3, 2016
Q4 2015 Codexis Inc Earnings Call
Mar 3, 2016
Q4 2015 Codexis Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -87.22% -18.13%
Operating margin -87.31% -18.59%
EBITD margin - -10.52%
Return on average assets -66.73% -16.34%
Return on average equity -143.48% -30.82%
Employees 91 -
CDP Score - -

Address

200 Penobscot Dr
REDWOOD CITY, CA 94063-4718
United States - Map
+1-650-4218100 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Codexis, Inc. is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company's CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale. The Company's pharmaceutical products include enzymes, pharmaceutical intermediates, active pharmaceutical ingredients (APIs) and Codex Biocatalyst Panels and Kits. The fine chemicals market consists of several market verticals, including food and food ingredients, animal feed, flavors and fragrances, and agricultural chemicals. The Company also uses its technology to develop an early stage, enzyme therapeutic product candidate for the treatment of phenylketonuria (PKU) in humans through oral administration.

Officers and directors

Thomas R. Baruch J.D. Independent Chairman of the Board
Bio & Compensation  - Reuters
John J. Nicols President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Gordon T. Sangster Chief Financial Officer, Senior Vice President
Age: 61
Bio & Compensation  - Reuters
Douglas T. Sheehy J.D. Executive Vice President, Chief Administrative Officer, General Counsel, Secretary
Age: 48
Bio & Compensation  - Reuters
James Lalonde Senior Vice President, Research & Development
Age: 54
Bio & Compensation  - Reuters
Pam P. Cheng Director
Age: 44
Bio & Compensation  - Reuters
Kathleen Sereda Glaub Director
Bio & Compensation  - Reuters
Patrick Y. Yang Ph.D. Director
Age: 68
Bio & Compensation  - Reuters
Byron L. Dorgan Independent Director
Age: 72
Bio & Compensation  - Reuters
Bernard J. Kelley Independent Director
Age: 73
Bio & Compensation  - Reuters